N/A
N=25
Movement Intervention for Memory Enhancement
Alzheimer Disease · Dementia · Cognitive Decline · Cognitive Impairment · Dementia, Alzheimer Type
Bottom Line
View on ClinicalTrials.gov: NCT03475316 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: Executive Function (EF). — 1.16; 0.99 z score
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Social Dancing (Behavioral); Treadmill Walking (Behavioral)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- Albert Einstein College of Medicine
- Primary completion
- Jun 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Executive Function (EF). |
1.16; 0.99 | — |
| SECONDARY Neuroplasticity. |
-9.68; -273.47; 6.82; -17.44; 81.30; 21.94 | — |
Summary
Dancing is a complex sensorimotor rhythmic activity that integrates cognitive, physical, and social components and is applicable to seniors with various fitness levels. Despite its popularity, there is a paucity of studies that have systematically examined the role of dancing in preventing or delaying cognitive decline in older adults at high risk for Alzheimer's disease and related dementias. This preliminary randomized clinical trial will help provide the evidence base to develop a definitive full-scale trial to support or refute prescription of social dancing to prevent further cognitive decline in older adults at high risk of Alzheimer's disease and related dementia.
Eligibility Criteria
Inclusion Criteria
- Adults aged 65 and older
- A score of ≤ 6 on the Memory Impairment Screen or ≥ 1 on the AD-8
- Plan to be in area for next year or more
- English speaking
- Willing to complete an Functional Magnetic Resonance Imaging (MRI)
Exclusion Criteria
- Presence of dementia based on previous physician diagnosis of dementia or dementia diagnosed by the study clinician at initial visit.
- Serious chronic or acute illness such as cancer (late stage, metastatic, or on active treatment), chronic pulmonary disease on ventilator or continuous oxygen therapy or active liver disease.
- Mobility limitations solely due to musculoskeletal or cardiovascular conditions that prevent participation in the intervention programs.
- Any medical condition or chronic medication use (e.g., neuroleptics) in the judgment of the screening clinician that will compromise safety or affect cognitive functioning.
- Terminal illness with life expectancy less than 12 months.
- Presence of progressive, degenerative neurologic disease (e.g., Parkinson's disease or Amyotrophic lateral sclerosis).
- Severe auditory or visual loss.
- Active psychoses or psychiatric symptoms (such as agitation) noted during the clinic visit that will prevent completion of study protocols.
- Either participation in competitive dancing or recreational dancing at a frequency >1/month in the past six months.
- Participation in other interventional study that overlaps with intervention period of this study.
Data sourced from ClinicalTrials.gov (NCT03475316). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.